Viking Therapeutics: Back the GLP-1 Contender Before Phase 3 Catalysts
Viking Therapeutics (VKTX) is a clinical-stage biotech focused on metabolic and endocrine disorders. Its dual GIP/GLP-1 candidate VK2735 is in phase 3 (injectable) and phase 2 (oral), positioning Viking as an under-the-radar competitor in the high-growth obesity therapeutics market. With a market cap of roughly $3.6B, a deep short-interest base, an…